- Shedding of infectious SARS-CoV-2 from airways in hospitalized COVID-19 patients in 1
- 2 relation to serum antibody responses
- Authors: Hedvig Glans*1,2, Sara Gredmark-Russ^{1,3}, Mikaela Olausson⁴, Sara Falck-Jones⁵, 3
- 4 Renata Varnaite³, Wanda Christ³, Kimia T. Maleki^{3,4}, Maria Lind Karlberg⁴, Sandra
- Broddesson⁴, Ryan Falck-Jones^{6, 7}, Max Bell^{6, 7}, Niclas Johansson^{1,2}, Anna Färnert^{1,2}, Anna 5
- 6 Smed-Sörensen⁵, Jonas Klingström^{3,4}, Andreas Bråve⁴

Affiliations

7

- 1. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden. 8
- 2. Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. 9
- 10 3. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
- Stockholm, Sweden. 11
- 4. Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden. 12
- 5. Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, 13
- 14 Stockholm, Sweden
- 6. Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, 15
- Stockholm, Sweden 16

18

- 7. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. 17
- 19 Corresponding author: Hedvig Glans, hedvig.glans@ki.se, phone number +46724698808,
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

21

22

23

24

25

26

27

28

To understand the risk of transmission of SARS-CoV-2 in hospitalized COVID-19 patients we simultaneously assessed the presence of SARS-CoV-2 RNA, live infectious virus in the airways, and virus-specific IgG and neutralizing antibodies in sera in 36 hospitalized COVID-19 patients. SARS-CoV-2 could be cultured from four patients, all with low or undetectable antibody response. Our data suggests that the level of SARS-CoV-2 antibodies may correlate to risk for shedding live SARS-CoV-2 virus in hospitalized COVID-19 patients.

Introduction

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

It is important to better understand the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission from coronavirus disease 2019 (COVID-19) patients. Many studies report PCR-detectable SARS-CoV-2-RNA in the airways over time (1-3), but little has been reported on shedding of infectious viruses from the airways in hospitalized COVID-19 patients. In the setting of mild COVID-19 infection, shedding of infectious virus has been described during the first week of symptoms (4). No viable virus could be isolated after 8 days, coinciding with the appearance of detectable antibodies to SARS-CoV-2 (5). In a larger study, with patients ranging from asymptomatic to severe, SARS-CoV-2 culture-positive airway samples declined to 6% at day 10 (6). In a cohort with 129 severely ill COVID-19 patients, the median duration of shedding of infectious virus was 8 days after symptom onset, with infectious virus found up to 20 days after symptom onset (7). Determinants for the detection of infectious SARS-CoV-2 were either viral loads above 7 log10 RNA copies/mL in airways or neutralizing antibody titres below 20 in sera (7). Even if there is one case report on a patient with SARS-CoV-2 shedding for 18 days even after seroconversion at day 10 (8), antibodies may be of importance in judging contagiousness. The aim of our study was to evaluate if infectious SARS-CoV-2 could be cultured from nasopharyngeal and sputum samples in hospitalized patients with symptoms exceeding 8 days and to evaluate if the SARS-CoV-2-specific antibody responses in serum correlated with shedding of infectious virus.

52

53

54

55

56

57

58

59

60

61

62

63

64

70

71

72

73

74

75

Results Thirty-six COVID-19 patients were enrolled in this study, the majority were men (n=25, 69%), and the median age was 60.5 years (range 25-77 years) (Table 1). The majority of the patients had an underlying risk factor for severe COVID-19 infection (Table 1) (9). Thirty-three (92%) patients received supplemental oxygen treatment. Fourteen (39%) patients were treated in the intensive care unit, of which 9 were treated with mechanical ventilation. Fourteen patients had received immunomodulatory treatment, and four had received remdesivir, prior to inclusion in the study (Table 1). Samples from the patients were collected at a median of 18 days (range 9-53 days) after selfreported onset of symptoms, and at a median of 8 days (range 1-44 days) after their positive diagnostic sample (Table 1). Twenty-three (64%) patients had SARS-CoV-2 RNA detected by PCR in airway samples, of which 14 were positive in nasopharynx and 18 in sputum (Supplementary Table 1).

SARS-CoV-2 could be cultured from airway samples in four patients (11% of all patients, 65 17.3% of PCR-positive patients) (Table 2). All four patients had underlying diseases potentially 66 increasing the risk of severe COVID-19 (9). Three of the patients had been symptomatic for 9-67 68 11 days before sampling. The fourth patient, with a haematological malignancy and leukopenia during hospitalization, still had infectious SARS-CoV-2 on day 16 after onset of symptoms. 69

Three (8.3%) patients had detectable but low levels of SARS-CoV-2 RNA in blood (Supplementary Table 1), however, none of the patients were culture positive for SARS-CoV-2 in the respiratory samples.

All but two patients had detectable levels of SARS-CoV-2-specific immunoglobulin G (IgG) in serum, with titers ranging from 1:40 to 1:2560. Neutralizing antibodies towards SARS-CoV-2 were detected in 33 of the 36 patients (Supplementary Table 1). The positive control, sampled

at day 5 after onset of symptoms, had no detectable SARS-CoV-2-specific antibodies, but was

positive for infectious virus in the airways (data not shown).

There was a strong positive correlation between total SARS-CoV-2-specific IgG titers and 78

neutralizing antibody titers (Spearman's correlation: $r_s = 0.689$, p < 0.001) (Figure 1A).

Patients sampled earlier after symptom onset, showed a variation in IgG titers and neutralizing

antibodies (Figure 1B and Supplementary Table 1). Patients with IF titers equal to or below

1:40 either displayed no detectable, or low levels of neutralizing antibodies (Supplementary

Table 1). Whereas, the distribution of the levels of SARS-CoV-2 IgG and neutralizing antibody

titers within the patients are similar, and with a general higher level of antibodies and

neutralizing titer in patients sampled during later times (Figure 1B), all four patients that

shedded infectious SARS-CoV-2 had low or no detectable IgG titers and neutralizing antibody

titers (Table 2 and Table 3).

Discussion

76

77

79

80

81

82

83

84

85

86

87

88

89

91

92

93

94

95

96

97

98

Viable SARS-CoV-2 were isolated from four patients. We could not detect viable SARS-CoV-90

2 virus from patients with SARS-CoV-2-specific IgG titers above 1:40, or with neutralizing

antibodies titers above 1:10. Seroconversion, with detectable neutralizing antibodies, was

observed in all 32 patients from whom no viable SARS-CoV-2 virus could be isolated from the

respiratory tract. In addition, no infectious virus could be isolated from the patients that were

SARS-CoV-2 RNA PCR negative.

In patients with a shorter symptom duration, there was a large variation in total specific IgG

and neutralizing antibody titers. Three of the culture-positive patients were sampled within 11

days after the onset of symptoms. However, the fourth patient with culturable SARS-CoV-2,

All rights reserved. No reuse allowed without permission.

an immunocompromised patient, was sampled at day 16 after the onset of symptoms, showing that infectious virus can be shed rather late during COVID-19 in immunocompromised patients. Similar to previous reports (7), our data suggest that individuals with low, or no, levels of neutralizing antibodies and total IgG antibodies have an increased risk of shedding live virus. Prior knowledge of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) present similar data, where SARS-CoV-1 could be isolated during the first 2 weeks, but not after day 22, of illness (10). However, to better understand the correlation between virus shedding and serological response in COVID-19 patients, larger studies need to be performed. The World Health Organization (WHO) recommends at least 10 days after symptom onset plus an additional 3 days without fever and respiratory symptoms, before releasing COVID-19 patients from isolation (11). Our data indicate that infectious SARS-CoV-2 could not be detected in the airways after day 14 after symptom onset despite detectable viral RNA by PCR unless immunocompromised patients. The latter finding is in concordance with a previous study also detecting viable viruses long after symptom onset in immunocompromised patients (12). Serological assay for SARS-CoV-2 may provide additional guidance in judging if a hospitalized patient may be shedding infectious SARS-CoV-2 virus, especially in the setting of immunocompromised COVID-19 patients.

Material and methods

Sample collection

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

Thirty-six patients with verified COVID-19 infection admitted to the Department of Infectious Diseases or the Intensive Care Unit at Karolinska University Hospital, Stockholm, Sweden, with a symptom duration >8 days and with a previous SARS-CoV-2 RNA positive nasopharynx or pharynx sample, were included in the study. One patient sampled 5 days after onset of

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

symptoms was included as a positive control for virus shedding. Samples for culture and SARS-CoV-2 real time-PCR (RT-PCR) were collected from nasopharynx (all patients), and, when possible, sputum (30 patients). Serum were collected from all patients for SARS-CoV-2 RT-PCR analysis and antibody analysis. **Ethical statement** The study was approved by the Swedish Ethical Review Authority, all relevant regulations for work with human participants were complied with, and patient samples were obtained according to the Declaration of Helsinki. Patients included in the study provided written informed consent. **RT-PCR** SARS-CoV-2 RT-PCR were performed on respiratory samples and in serum. RT-PCR targeting the envelope(E)- and RNA dependent RNA polymerase (rdrp)-genes were used to detect the presence of SARS-CoV-2 RNA (13). Isolation of live SARS-CoV-2 from patient material Virus isolation was carried out at a biosafety level 3 (BSL3) laboratory. For the virus cultures, 100 μL sample from nasopharyngeal swabs (NPS) and 100 μL tracheal secretion or sputum collected from a total of 37 patients, the positive control patient included, were inoculated in duplicate on Vero-E6 cells. Inoculation was carried out for 1.5 h at 37 °C and 5 % CO2 and medium (Dulbecco's Modified Eagle's Medium, DMEM) supplemented with 5 % fetal bovine serum (FBS), 10X Antibiotic-Antimycotic, 0.6 ug/mL penicillin, 60 ug/mL streptomycin, 2

mM L-glutamine, 20 mM HEPES) were then added. Cells were continuously monitored for cytopathic effect (CPE). After 10 days the cultures were harvested and supernatants were analyzed with RT-PCR specific for the SARS-CoV-2 E-gene and (rdrp)-gene (13).

Sequencing of SARS-CoV-2

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

All primary clinical samples and samples from positive virus cultures were sequenced in order to exclude contamination. Sequencing libraries were constructed using the Ion AmpliSeq SARS-CoV-2 Research Panel (Thermo Fisher Scientific, MA, USA). cDNA was synthesized from SARS-CoV-2 RNA using SuperScript IV VILO Master Mix (Thermo Fisher Scientific, MA, USA) and incubated at 25 °C for 10 min, 50 °C for 10 min and 85 °C for 5 min. Automated library preparation and amplification was performed on an Ion Chef instrument with AmpliSeq Chef reagents and specific SARS-CoV-2 primers (Thermo Fisher Scientific, MA, USA). Libraries were quantified with TaqMan-based qPCR, using custom primers and probe targeting the flanking A- and P-adapters of the constructed libraries (Integrated DNA Technologies, IA, USA). The qPCR protocol was initiated by a holding stage at 95 °C for 20 s, followed by 40 cycles of 95 °C for 1 s and 60 °C for 20 s. Libraries were normalized to a final concentration of 35 pM and prepared for sequencing with the Ion 540 Kit-Chef (Thermo Fisher Scientific, MA, USA) for 200 base-pair reads. Sequencing was performed on an Ion GeneStudio S5 Sequencing System (Thermo Fisher Scientific, MA, USA). Raw reads were trimmed and filtered using default parameters, then analyzed with the Ion Torrent Suite software plugin coverageAnalysis, where an average read coverage of 20x for every amplicon of a sample was required to pass quality control. Variant calling against the SARS-CoV-2 reference sequence (NC 045512.2) was performed by the Ion Torrent Suite software plugin variantCaller.

All rights reserved. No reuse allowed without permission.

Immunofluorescence assay (IFA)

170

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

171 IFA was performed as previously described (13). Briefly, SARS-CoV-2-infected Vero cells

mixed with uninfected Vero cells were used as target cells. Serum samples were heat-

inactivated at 56°C for 30 minutes prior to analysis and two-fold serially diluted starting at 1:20.

The titer of IgG in each serum sample was determined by the inverted dilution factor value for

the highest dilution with positive staining.

Micro-neutralization assay

IFA was performed as previously described (9). Heat inactivated (56°C for 30 minutes) serum

were diluted in a two-fold dilution serie starting from 1:10. Each sample was prepared in

duplicates. Each dilution was mixed with an equal volume of 4000 TCID₅₀/ml SARS-CoV-2

(60 μl serum plus 60 μl virus). After incubation, 100 μL of the mixtures were added to Vero

E6 cells seeded on 96-well plates and incubated at 37 °C 5% CO₂. Four days later the cells were

inspected for signs of cytopathic effect (CPE) by optical microscopy. Each well was scored as

either 'neutralizing' if less than 50% of the cell layer showed signs of CPE, or 'non-neutralizing'

if ≥50% CPE was observed.

References

- 188 1. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load
- in Upper Respiratory Specimens of Infected Patients. The New England journal of medicine.
- 190 2020;382(12):1177-9.
- 191 2. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
- shedding and transmissibility of COVID-19. Nature medicine. 2020;26(5):672-5.

- 193 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
- mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- 195 Lancet (London, England). 2020;395(10229):1054-62.
- 196 4. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- 197 Virological assessment of hospitalized patients with COVID-2019. Nature.
- 198 2020;581(7809):465-9.
- 199 5. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.
- 200 Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe
- 201 COVID-19. Nature medicine. 2020;26(4):453-5.
- 202 6. Singanayagam A, Patel M, Charlett A, Bernal JL, Saliba V, Ellis J, et al. Duration of
- 203 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,
- 204 England, January to May 2020. Eurosurveillance. 2020;25(32):2001483.
- van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba
- N, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019
- 207 (COVID-19): duration and key determinants. medRxiv. 2020:2020.06.08.20125310.
- 208 8. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus
- shedding even after seroconversion in a patient with COVID-19. The Journal of infection.
- 210 2020;81(2):318-56.
- 9. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
- Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the
- 213 Chinese Center for Disease Control and Prevention. Jama. 2020.
- 214 10. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, et al. Detection of SARS
- coronavirus in patients with suspected SARS. Emerging infectious diseases. 2004;10(2):294-9.
- 216 11. WHO. Criteria for releasing COVID-19 patients from isolation.

- 12. Ridgway JP, Shah NS, Robicsek AA. Prolonged shedding of severe acute respiratory 217
- 218 coronavirus virus 2 (SARS-CoV-2) RNA among patients with coronavirus disease 2019
- (COVID-19). Infection control and hospital epidemiology. 2020:1-2. 219
- 13. Varnaitė R, García M, Glans H, Maleki KT, Sandberg JT, Tynell J, et al. Expansion of 220
- SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in 221
- Hospitalized COVID-19 Patients. Journal of Immunology. In Press. 2020. 222

Acknowledgements

223

224

231

232

- 225 The authors would like to thank the patients that contributed to the study. Further, authors would
- like to thank Karin Tegmark-Wisell and Shaman Muradrasoli at the Public Health Agency of 226
- Sweden for contributing to the design of the study. Parts of this study was supported by 227
- Marianne and Marcus Wallenberg Foundation (SGR), grants provided by region Stockholm 228
- (ALF project) (SGR), grants from the Swedish Research Council (ASS, JK) and the Swedish 229
- 230 Heart and Lung Foundation (ASS).

Authors contributions

- 233 H.G., S.G.R. and A.B. led the study.
- M.O., M.L.K., S.B., J.K., and A.B. designed experiments and optimized assays. 234
- H.G., S.F.J., R.F.J. and M.B. included patients and summarized clinical information. 235
- M.O., K.T.M, W.C, M.L.K., S.B., and J.K. performed experiments. 236

H.G., S.G.R., M.O., S.F.J., R.V., W.C., K.T.M., M.L.K., S.B., N.J., A.F., A.S.S., J.K. and A.B. contributed to design and conceptualization of the study, discussed data analysis and interpreted the results. H.G. and S.G.R wrote the paper, with input provided by all co-authors **Conflict of interest** Authors declare no conflicts of interest. Figure Legend Figure 1.A. Correlation between anti-SARS-CoV-2 IgG titers and neutralizing antibodies titers. B. SARS-CoV-2-specific and neutralizing antibody levels in patients plotted on a timeline.

Table 1. COVID-19 patient characteristics (n=36).

257

Cohort characteristics	no.	%			
Male	25	69			
Age, years, median (range)	60.5 (25-7	7)			
Symptom onset to sampling, days, median	18 (9-53)				
(range)					
Days since diagnosis (positive SARS-CoV-2	8 (1-44)				
PCR), median (range)	8 (1-44)				
Comorbidities					
Diabetes mellitus type II	13	36			
Hypertension	11	31			
Lung disease	8	22			
Cardiovascular disease	7	19			
BMI >25	6	17			
Malignancy	3	8			
Treatment		<u> </u>			
Supplemental oxygen	33	92			
Mechanical ventilation	9	25			
ICU treatment*	14	39			
Immunomodulatory drugs [†]	14	39			
Antiviral treatment (remdesivir)	4	11			

Abbreviations: BMI: body mass index, ICU: intensive care unit 258

* ICU treatment before study sampling (n=11), ICU treatment during study sampling (n=2), 259

ICU treatment after study sampling (n=1)

† Treatment before sampling Corticosteroids (n=13), tociluzimab (n=2) or anakinra (n=1). Two patients had prednisolone treatment before COVID-19 and had extra corticosteroids added as treatment.

261

262

263

Table 2. Antibody and virus levels in SARS-CoV-2 culture-positive patients

Patient ID*	SARS-CoV-2 PCR (Ct value)			SARS- cultur	-CoV-2 e	Anti- SARS- CoV-2	Neutralizing antibody titer	Days after onset of symptom
	NPH	Sputum	Serum	NPH	Sputum	IgG titer		
1	19	21	neg	pos	pos	<20	<10	16
2	24	28	neg	pos	neg	<20	<10	9
3†	25	19	neg	pos	neg	40	<10	9
4 [†]	26	20	neg	pos	neg	40	10	11

*Comorbidities: patient 1 - follicular lymphoma, diabetes mellitus II, chronic obstructive pulmonary disease, ST elevation myocardial infarction (STEMI); patient 2 - diabetes mellitus II, hypertension, chronic kidney failure; patient 3 - asthma, hypothyroidism; patient 4 - asthma, obesity.

- †Betametason treatment (4 mg) within 24 hours before sampling.
- Abbreviations: neg: negative, NPH: nasopharynx, pos: positive

Table 3. SARS-CoV-2-specific antibody titers in relation to detectable SARS-CoV-2 RNA

and infectious SARS-CoV-2 in nasopharynx in all COVID-19 patients (n=36).

Total SARS- CoV-2 IgG	Number of patients	PCR positive		PCR negative		Culture positive		Culture negative	
titer		no.	%	no.	%	no.	%	no.	%
<20	2	2	100	0	0	2	100	0	0
20 to 40	5	3	60	2	40	2	40	3	60
160 to 320	4	3	75	1	25	0	0	4	100
640 to 2560	25	6	24	19	76	0	0	25	100
		PCR positive		PCR negative		Culture positive		Culture negative	
Neutralizing antibody	Number of patients	_		_	e		-		
U		_		_	e %		_		
antibody		posi	tive	negativ		positiv	e	negative	<u> </u>
antibody titer	of patients	posi no.	tive %	negative n	%	positive no.	e %	negative no.	0/0
antibody titer <10	of patients	posi no.	tive % 100	negative n	%	positive no.	e % 100	negative no.	% 0


*neutralizing titer 10


281

282

283

Figure 1





- Total specific IgG
 - Neutralizing antibody titer